Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20173285Keywords:
DAS-28, Rheumatoid arthritis, RAPID-3Abstract
Background: Rheumatoid arthritis (RA) a chronic autoimmune inflammatory disease and Methotrexate being widely used as monotherapy and in combination for the treatment of RA. Combination therapy provides additional or even more potentiating effects, therefore have been widely used. This study is aimed at comparing the efficacy and safety of Methotrexate either alone or in combination.
Methods: This study was conducted for one year from 1st January to 31st December 2015. 52 patients diagnosed with RA were included in this study and were divided in two groups, Group-1 (n=29) patients received methotrexate (MTX) 7.5-15mg/week and Group-2 (n=23) patients received methotrexate 7.5mg once a week + Hydroxychloroquine (HCQ) 200mg twice daily. The patients were followed up for a period of 16 weeks. Statistical analysis was done by using graph pad insta and p value of <0.05 was considered significant.
Results: A total of 52 patients were included in the study. The mean age of patients was 50.53±14.81 years. 43 (82.69%) patients were females and 9 (17.30%) were males. 23 (44.23%) patients had positive family history of the disease. The Rheumatoid factor was positive in 42 (80.70%) and anti-CCP was raised in 50 (96.15%) patients. The RAPID-3 and DAS-28 scores on intragroup comparison was highly significant (p <0.0001) and the intergroup comparison was significant (p <0.01) between baseline and 16 weeks in both the groups. The improvement in inflammatory marker CRP was highly significant on intragroup (p <0.0001) and intergroup (p<0.001) comparison between baseline and 16 weeks in both the groups. The mean changes in Vitamin-D3 between baseline and at 16 weeks were insignificant (p >0.05) in both the groups. Total of Adverse drug reactions reported were 42 (50.60%) in group-1 and 41 (49.40%) in group-2.
Conclusions: The combination therapy was found to be more efficacious than MTX monotherapy in improving symptoms and quality of life. The adverse drug reactions were mild, more in combination therapy and none of the patients required withdrawal of treatment.
References
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the united states. Arthritis Rheum. 2008;58:15-25.
Shah A, St. Clair EW. Rheumatoid Arthritis. In Longo DL, Fauci, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. 18th Edition, Mc Graw Hill; 2012:2738-2752.
Symmons DM, Barrett EM, Bankhead CR, Scott DI, Silman AJ. The occurrence or rheumatoid arthritis in the United Kingdom: results from the Norflok Arthritis Register. Br J Rheumatol. 1994;33:735-79.
Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100-8.
Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. The Lancet. 2002 Apr 6;359(9313):1173-7.
Bajrakatri IH, Cico TB, Meka VS, Bajrataki H, Saiti V, Krasniqi B et al. Demographic Features of patients with rheumatoid arthritis in Kosovo. Med Arh. 2014;68(6):407-10.
Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. NEJM. 2014;370:2377-86.
O’ Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. NEJM 2013;369:307-18.
Koumantaki Y, Giziaki E, Linos A, Kontomerkos A, Kaklamanis P, Vaiopoulous G, et al. Family History as a risk factor for rheumatoid arthritis. J Rheumatol. 1997;24(8):1522-6.
Mathur R, Singh H, Arya S, Singh V. Comparative evaluation of efficacy of Leflunomide versus combination of methotrexate and hydroxychloroquine in patients with Rheumatoid Arthritis. Indian Journal of Rheumatology. 2016 ;11(2): 86-90.
Song Y, Li-an Zhu, Wang SL, Leng L, Bucala R, Lu LG. Multi dimensional Health Assessment Questionnaire in China: Reliability, Validity and Clinical Value in Patients with Rheumatoid Arthritis. 2014;9(5):1-9.
Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-72.
Lipsky PE, Desiree MFM, Heijde VD, St. Clair W, Daniel E, Ferdinand C, et al. Infliximab and Methotrexate in the treatment of rheumatoid arthritis. NEJM. 2000;343:1594-602.
Rossini M, Bongi SM, Montanga GL, Minisola G, Malavolta N, Berini L, et al. Vitamin D deficiency in rheumatoid arthritis: Prevalence, determinants and associations with disease activity and disability. Arthritis research and therapy. 2010;12(216):2-7.
Linda AM, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D is inversely associated with Rheumatoid Arthritis. Arthritis and Rheumatism. 2004;50(1):72-7.
Bathon JM, Marthin RW, Fleischmann RM, Tesser JR, Keystone E, Schiff MH, et al. A comparison of Etanercept and Methotrexate in patients with early rheumatoid arthritis. NEJM. 2000;343(22):1586-93.
O’Dell JR, Claire E, Haire RN, Erikson N, Drymalski W, Plamer W, et al. Treatment of rheumatoid arthritis with methotrexate alone, Sulfasalazine and hydroxychloroquine, or a combination of all three medications. NEJM. 1996;334:1287-91.
